Private Equity Newsletter
Cornering the EU Market: the need for Creative Strategies
EBR When it comes to the accessibility of the EU pharmaceutical market, it is clear that a number of factors have changed in the past few years. Evolution or revolution?
Reaching the bottom?
Financial Advisory Newsletter, 2nd Edition
Q2 - 2008
VCs keep investing but the scope’s changing!
Financial Advisory Newsletter, 1st Edition
Q1 - 2008
Roadmap for success in oncology
SCRIP Executive Briefing, Vol 1 No 3 The worldwide oncology market is projected to outgrow the rest of the pharma industry, becoming the number one therapeutic class in revenue terms by 2011. So will oncology become pharma’s new “holy grail”?
“Up or Out in Oncology” Executive Summary only
Bionest Disease Area Review
Innovation takes the prize
Pharmaceutical Executive A celebration of the first annual Prix Galien
Vaccines : Growth Boosters
Exane BNP Paribas Equity Research Report
Reaching Maturity – New Challenges for an Evolving Industry
VentureCapital Magazine. (article in German)